货号:A114568 同义名: GSK2816126A;GSK2816126
GSK126 is a potent, highly selective EZH2 methyltransferase inhibitor with IC50 of 9.9 nM, > 1000-fold selective for EZH2 over 20 other human methyltransferases.
规格 | 价格 | 会员价 | 库存 | 数量 | |||
---|---|---|---|---|---|---|---|
{[ item.pr_size ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_am, item.pr_size) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} | 现货 | 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解
产品名称 | BET ↓ ↑ | bromodomain ↓ ↑ | BRPF ↓ ↑ | CBP/beta-catenin ↓ ↑ | p300/CBP ↓ ↑ | 其他靶点 | 纯度 | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
MS436 |
++
BRD4 (1), Ki: <0.085 μM BRD4 (2), Ki: 0.34 μM |
99%+ | |||||||||||||||||
CPI-203 |
+++
BRD4, IC50: 37 nM |
99+% | |||||||||||||||||
GSK1324726A |
+++
BRD4, IC50: 22 nM BRD2, IC50: 31 nM |
99%+ | |||||||||||||||||
PFI-1 |
++
BRD4, IC50: 0.22 μM BRD2, IC50: 98 nM |
98% | |||||||||||||||||
Apabetalone |
+
BD2, IC50: 0.51 μM |
99% | |||||||||||||||||
(+)-JQ1 |
+++
BRD4 (1), IC50: 77 nM BRD4 (2), IC50: 33 nM |
98% | |||||||||||||||||
I-BET151 |
+
BRD4, IC50: 0.5 μM BRD3, IC50: 0.25 μM |
98% | |||||||||||||||||
Molibresib |
+++
BET proteins, IC50: 35 nM |
99%+ | |||||||||||||||||
I-BRD9 |
+++
BRD9, pIC50: 7.3 BRD4, pIC50: 5.3 |
99%+ | |||||||||||||||||
BI-7273 |
++++
BRD7, IC50: 117 nM BRD9, IC50: 19 nM |
99+% | |||||||||||||||||
Pelabresib |
+++
BRD4-BD1, IC50: 39 nM |
98% | |||||||||||||||||
ARV-825 |
+++
BRD4 BD1, Kd: 90 nM BRD4 BD2, Kd: 28 nM |
99%+ | |||||||||||||||||
Birabresib | 99%+ | ||||||||||||||||||
BI 2536 |
+++
BRD4, Kd: 37 nM |
c-Myc | 99%+ | ||||||||||||||||
Bromosporine |
++
BRD2, IC50: 0.29 μM BRD9, IC50: 0.122 μM |
++++
CECR2, IC50: 17 nM |
99%+ | ||||||||||||||||
XMD8-92 |
++
BRD4 (1), Kd: 170 nM |
99%+ | |||||||||||||||||
Mivebresib | ✔ | 99%+ | |||||||||||||||||
BI-9564 |
++++
BRD9, Kd: 5.9 nM BRD7, Kd: 73 nM |
++
CECR2, Kd: 77 nM |
98% | ||||||||||||||||
AZD5153 6-Hydroxy-2-naphthoic acid |
++++
FL-BRD4, IC50: 5 nM |
99%+ | |||||||||||||||||
PLX51107 |
++++
BRD3 BD1, Kd: 2.1 nM BRD4 BD2, Kd: 1.7 nM |
99%+ | |||||||||||||||||
FL-411 |
+
BRD4(1), IC50: 0.43 μM |
99%+ | |||||||||||||||||
ABBV-744 | ✔ | 99%+ | |||||||||||||||||
dBET6 |
++++
BRD4, IC50: 14 nM |
99%+ | |||||||||||||||||
dBET1 |
++++
BRD4, IC50: 20 nM |
99%+ | |||||||||||||||||
MZ1 |
++++
Brd3(BD2), Kd: 13 nM Brd2(BD2), Kd: 62 nM |
99%+ | |||||||||||||||||
dBET57 |
+
BRD4BD1, DC50: 500 nM |
99%+ | |||||||||||||||||
SF2523 |
+
BRD4, IC50: 241 nM |
DNA-PK | 99%+ | ||||||||||||||||
INCB054329 |
++++
BRD4-BD1, IC50: 119 nM BRD3-BD1, IC50: 9 nM |
99% | |||||||||||||||||
INCB-057643 | ✔ | 99%+ | |||||||||||||||||
(E/Z)-ZL0420 |
+++
BRD4 BD2, IC50: 32 nM BRD4 BD1, IC50: 27 nM |
99%+ | |||||||||||||||||
BMS-986158 | ✔ | 99%+ | |||||||||||||||||
BRD4 Inhibitor-10 |
++++
BRD4-BD1, IC50: 5 nM BRD4-BD2, IC50: 41 nM |
97% | |||||||||||||||||
A1874 | ✔ | 99%+ | |||||||||||||||||
Y06036 |
++
BRD4 (1), Kd: 82 nM |
99%+ | |||||||||||||||||
Alobresib | ✔ | NF-κB | 98% | ||||||||||||||||
ODM-207 | ✔ | 99% | |||||||||||||||||
GSK778 |
+++
BRD2-BD1, IC50: 75nM BRD4-BD1, IC50: 143 nM |
97% | |||||||||||||||||
SRX3207 |
+
BRD41, IC50: 3070 nM BRD42, IC50: 3070 nM |
Syk | 98% | ||||||||||||||||
GSK046 |
+++
BRD4BD2, IC50: 214 nM BRD3BD2, IC50: 98 nM |
98% | |||||||||||||||||
GSK620 | ✔ | 97% | |||||||||||||||||
Thalidomide-NH-C4-NH-Boc | ✔ | 98% | |||||||||||||||||
Trotabresib | ✔ | 99% | |||||||||||||||||
NHWD-870 | ✔ | 98% | |||||||||||||||||
CFT8634 |
++++
BRD9, DC50: 3 nM |
98% | |||||||||||||||||
GSK2801 |
++
BAZ2B, Kd: 136 nM BAZ2A, Kd: 257 nM |
99%+ | |||||||||||||||||
KG-501 | ✔ | 99%+ | |||||||||||||||||
UNC 669 |
+
L3MBTL4, IC50: 6 μM L3MBTL3, IC50: 35 μM |
98% | |||||||||||||||||
PFI-3 |
+++
SMARCA2A, Kd: 72 nM SMARCA4, Kd: 55 nM |
99%+ | |||||||||||||||||
UNC1215 |
+++
L3MBTL3- D274A, IC50: 3.5 μM L3MBTL3, IC50: 120 nM |
99%+ | |||||||||||||||||
EED226 |
++
EED, Kd: 82 nM PRC2, Kd: 114 nM |
99%+ | |||||||||||||||||
BRD9539 | ✔ | 98% | |||||||||||||||||
UNC926 |
+
L3MBTL1, Kd: 3.9 μM |
99% | |||||||||||||||||
666-15 |
++
CREB, IC50: 81 nM |
99%+ | |||||||||||||||||
UNC6852 |
+
EED, IC50: 247 nM |
98% | |||||||||||||||||
BAZ1A-IN-1 |
+
BAZ1A, Kd: 0.52 μM |
99%+ | |||||||||||||||||
PFI-4 |
++
BRPF1, IC50: 80 nM BRPF2, IC50: 7.9 μM |
99%+ | |||||||||||||||||
OF-1 |
++
BRPF2, Kd: 500 nM BRPF1B, Kd: 100 nM |
99%+ | |||||||||||||||||
GSK-5959 |
++
BRPF3, pIC50: 7.1 BRPF2, pIC50: 5.2 |
99% | |||||||||||||||||
GSK6853 |
++++
BRPF1, pIC50: 8.1 |
99%+ | |||||||||||||||||
NI-42 |
++++
BRPF1, IC50: 48 nM BRPF3, IC50: 260 nM |
99%+ | |||||||||||||||||
E-7386 |
+++
CBP/beta-catenin, IC50: 0.0484 μM |
97% | |||||||||||||||||
I-CBP112 |
++
p300, Kd: 167 nM CBP, Kd: 151 nM |
98+% | |||||||||||||||||
Histone Acetyltransferase Inhibitor II |
+
p300, IC50: 5 μM |
98% | |||||||||||||||||
C646 |
+
p300/CBP, Ki: 400 nM |
99%+ | |||||||||||||||||
Anacardic Acid |
+
PCAF, IC50: 5 μM p300/CBP, IC50: 8.5 μM |
99%+ | |||||||||||||||||
SGC-CBP30 |
++++
EP300, IC50: 38 nM CREBBP, IC50: 21 nM |
99%+ | |||||||||||||||||
Nordihydroguaiaretic acid | ✔ | HER2,IGF-1R | 99%+ | ||||||||||||||||
Curcumin |
+
p300, IC50: ~25 μM |
Ferroptosis,Nrf2,NF-κB | 98% | ||||||||||||||||
PF-CBP1 HCl |
++
p300/CBP, IC50: 363nM CREBBP, IC50: 125nM |
97% | |||||||||||||||||
CPI-637 |
+++
EP300, IC50: 0.051 μM CBP, IC50: 0.03 μM |
99%+ | |||||||||||||||||
Foscenvivint | ✔ | β-catenin | 99%+ | ||||||||||||||||
A-485 |
++
p300 HAT, IC50: 0.06 μM |
99%+ | |||||||||||||||||
GNE-781 |
+
BRD4(1), IC50: 5100 nM |
++++
CBP, IC50: 0.94 nM |
98% | ||||||||||||||||
NEO2734 |
+++
BET, IC50: <30 nM |
+++
p300/CBP, IC50: <30 nM |
99%+ | ||||||||||||||||
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 |
产品名称 | Histone Methyltransferase ↓ ↑ | 其他靶点 | 纯度 | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
BRD4770 | ✔ | 99%+ | |||||||||||||||||
UNC1999 |
+++
EZH2, IC50: 2 nM EZH1, IC50: 45 nM |
99%+ | |||||||||||||||||
EPZ005687 |
++
EZH2, Ki: 24 nM |
98+% | |||||||||||||||||
EPZ015666 |
+++
PRMT5, Ki: 5 nM |
99%+ | |||||||||||||||||
3-Deazaneplanocin A HCl |
++++
S-adenosylhomocysteine hydrolase, Ki: 50 pM |
99%+ | |||||||||||||||||
Tazemetostat |
+++
EZH2, IC50: 11 nM EZH2, Ki: 2.5 nM |
98% | |||||||||||||||||
GSK126 |
++
EZH2, IC50: 9.9 nM |
99%+ | |||||||||||||||||
MI-3 |
+
Menin-MLL, IC50: 648 nM |
98% | |||||||||||||||||
MM-102 |
++
MLL1, IC50: 0.4 μM |
99% | |||||||||||||||||
EI1 |
++
Ezh2 (wild-type), IC50: 15 nM EZH2 (Y641F), IC50: 13 nM |
98% | |||||||||||||||||
SGC0946 |
++++
DOT1L, IC50: 0.3 nM |
99%+ | |||||||||||||||||
PFI-2 HCl |
++++
SETD7, IC50: 2 nM SETD7, Ki: 0.33 nM |
99%+ | |||||||||||||||||
Pinometostat |
++++
DOT1L, Ki: 80 pM |
99%+ | |||||||||||||||||
EPZ004777 |
+++
DOT1L, IC50: 0.4 nM |
99%+ | |||||||||||||||||
Entacapone |
++
COMT, IC50: 151 nM |
95% | |||||||||||||||||
UNC0379 |
+
SETD8, IC50: 7.9 μM |
99%+ | |||||||||||||||||
Menin-MLL inhibitor MI-2 |
+
Menin-MLL, IC50: 446 nM |
98% | |||||||||||||||||
GSK343 |
+++
EZH2, IC50: 4 nM EZH1, IC50: 240 nM |
99%+ | |||||||||||||||||
BIX-01294 3HCl |
+
G9a, IC50: 2.7 μM |
99%+ | |||||||||||||||||
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 |
靶点 |
|
描述 | EZH2 is the enzymatic subunit of PRC2 (Polycomb repressive complex 2), a complex that can methylate lysine 27 of histone H3 (H3K27) to promote transcriptional silencing. GSK126 is a potent inhibitor of EZH2 and inhibits both wild-type and mutant EZH2 methyltransferase activity with similar potencies (Kiapp=0.5 - 3 nM, measure by enzymatic activity) and has more than 1,000-fold selectivity for EZH2 as compared with other methyltransferases and 150-fold as compared to EZH1 (Kiapp = 89 nM). GSK126 induced a 50% loss of H3K27me3 in both EZH2 wild-type and mutant DLBCL cell lines at concentrations ranging from 7 - 252 nM independent of EZH2 mutation status (treated with GSK126 for 48h). GSK126 most potently inhibited H3K27me3, followed by H3K27me2 and H3K27me1 were only weakly reduced at the highest inhibitor concentration, with no effect on total histone H3 and PRC2 components. Following 10 days of once-daily dosing of GSK126 in mice using subcutaneous xenografts of KARPAS-422 and Pfeiffer cells, on dose 15 - 150 mg/kg, global H3K27me3 decreased and EZH2 targeted genes (TXNIP and TNFRSF21) expression increased in a dose dependent fashion. With daily 50 mg/kg dosing, complete tumor growth inhibition can be observed in both KARPAS-422 and Pfeiffer cell models. Complete tumor eradication can be observed on dose of 150 mg/kg daily or 300 mg/kg twice a week[1]. |
作用机制 | GSK126 is the SAM-competitive inhibitor of PRC2[1]. |
细胞系 | 浓度 | 检测类型 | 检测时间 | 活动说明 | 数据源 |
human A549 cells | Cytotoxic assay | 72 h | Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by WST-1 assay, GI50=18.7 μM. | 24767850 | |
human Daudi cells | Cytotoxic assay | 72 h | Cytotoxicity against human Daudi cells assessed as growth inhibition after 72 hrs by WST-1 assay, GI50=11.2 μM. | 24767850 | |
human HeLa cells | Function assay | 72 h | Inhibition of EZH2 in human HeLa cells assessed as reduction in H3K27me3 levels incubated for 72 hrs by ELISA method, IC50=0.28 μM. | 26189078 | |
human PC3 cells | Cytotoxic assay | 72 h | Cytotoxicity against human PC3 cells assessed as growth inhibition after 72 hrs by WST-1 assay, GI50=9.4 μM. | 24767850 | |
Dose | Mice: 2.5 mg/kg[2] (i.v.); min = 125 mg/kg, max = 1000 mg/kg[3] (p.o.) | ||||||||||||||
Administration | i.v., p.o. | ||||||||||||||
Pharmacokinetics |
|
计算器 | ||||
存储液制备 | 1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
1.90mL 0.38mL 0.19mL |
9.49mL 1.90mL 0.95mL |
18.99mL 3.80mL 1.90mL |
CAS号 | 1346574-57-9 |
分子式 | C31H38N6O2 |
分子量 | 526.672 |
别名 | GSK2816126A;GSK2816126 |
运输 | 蓝冰 |
存储条件 |
液体 -20°C:3-6个月-80°C:12个月 粉末 Keep in dark place,Sealed in dry,2-8°C |
溶解度 |
DMSO: 12 mg/mL(22.78 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO |
动物实验配方 |
IP 5% DMSO+water 0.8 mg/mL clear PO 0.5% CMC-Na 48 mg/mL suspension |